Unexpected Tc-pertechnetate avidity of lymph node metastases predicts better response to radioiodine therapy in differentiated thyroid cancer patients with lymph node metastases.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
752 patients with DTC and LNM treated at Zhejiang Cancer Hospital between May 2012 and December 2017.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] In patients with DTC and LNM, LNM uptake of Tc-pertechnetate is a rare phenomenon. Patients with Tc-pertechnetate-avid LNMs were more likely to benefit from I therapy, even after adjustment for age, I treatment frequency, and initial I activity.
[OBJECTIVE] To investigate the value of Tc-pertechnetate scan in postoperative differentiated thyroid cancer (DTC) patients with lymph node (LN) metastases (LNM) uptake Tc-pertechnetate, especially th
- 표본수 (n) 88
APA
Liu J, Li X, et al. (2024). Unexpected Tc-pertechnetate avidity of lymph node metastases predicts better response to radioiodine therapy in differentiated thyroid cancer patients with lymph node metastases.. American journal of nuclear medicine and molecular imaging, 14(1), 63-71. https://doi.org/10.62347/PBCV5827
MLA
Liu J, et al.. "Unexpected Tc-pertechnetate avidity of lymph node metastases predicts better response to radioiodine therapy in differentiated thyroid cancer patients with lymph node metastases.." American journal of nuclear medicine and molecular imaging, vol. 14, no. 1, 2024, pp. 63-71.
PMID
38500743
Abstract
[OBJECTIVE] To investigate the value of Tc-pertechnetate scan in postoperative differentiated thyroid cancer (DTC) patients with lymph node (LN) metastases (LNM) uptake Tc-pertechnetate, especially the predictive value to their response to radioiodine-131 (I) therapy.
[METHODS] This retrospective study collected 752 patients with DTC and LNM treated at Zhejiang Cancer Hospital between May 2012 and December 2017. Depending on the ability of LNM uptake Tc-pertechnetate, the patients were grouped as the Tc-pertechnetate-avid (n=88) vs. Tc-pertechnetate-non-avid (n=664) groups. And Propensity score matching (PSM) was performed at a 1:4 ratio to reduce confounding bias.
[RESULTS] In the PSM analysis, the 1:4 matched cohort comprised 752 patients (88 with Tc-pertechnetate-avid LNM, 664 with Tc-pertechnetate-non-avid LNM). Patients' age, initial I activity and frequency of iodine therapy were included as covariates. After PSM analysis, 363 patients (Tc-pertechnetate-avid group, n=83; Tc-pertechnetate-non-avid group, n=280) were successfully matched. Among the 363 PSM-matched patients, 48/83 (57.8%) in the Tc-pertechnetate-avid group and 158/280 (56.4%) in the Tc-pertechnetate-non-avid group had two or more I treatments. The nsTg and the percentage of changes in ssTg between the Tc-pertechnetate-avid and Tc-pertechnetate-non-avid groups were significantly different ([0.05 (0.04 to 0.90) vs. 0.40 (0.04 to 4.92), =0.018] and [-88% (-98%, -50%) vs. -66% (-86%, -30%), < 0.001], respectively). No significant differences were observed between the two groups in the other parameters (age, pathological type, distant metastasis, follow-up time, AJCC TNM stage, initial I treatment activity, and I treatment frequency) after PSM (all > 0.05).
[CONCLUSION] In patients with DTC and LNM, LNM uptake of Tc-pertechnetate is a rare phenomenon. Patients with Tc-pertechnetate-avid LNMs were more likely to benefit from I therapy, even after adjustment for age, I treatment frequency, and initial I activity.
[METHODS] This retrospective study collected 752 patients with DTC and LNM treated at Zhejiang Cancer Hospital between May 2012 and December 2017. Depending on the ability of LNM uptake Tc-pertechnetate, the patients were grouped as the Tc-pertechnetate-avid (n=88) vs. Tc-pertechnetate-non-avid (n=664) groups. And Propensity score matching (PSM) was performed at a 1:4 ratio to reduce confounding bias.
[RESULTS] In the PSM analysis, the 1:4 matched cohort comprised 752 patients (88 with Tc-pertechnetate-avid LNM, 664 with Tc-pertechnetate-non-avid LNM). Patients' age, initial I activity and frequency of iodine therapy were included as covariates. After PSM analysis, 363 patients (Tc-pertechnetate-avid group, n=83; Tc-pertechnetate-non-avid group, n=280) were successfully matched. Among the 363 PSM-matched patients, 48/83 (57.8%) in the Tc-pertechnetate-avid group and 158/280 (56.4%) in the Tc-pertechnetate-non-avid group had two or more I treatments. The nsTg and the percentage of changes in ssTg between the Tc-pertechnetate-avid and Tc-pertechnetate-non-avid groups were significantly different ([0.05 (0.04 to 0.90) vs. 0.40 (0.04 to 4.92), =0.018] and [-88% (-98%, -50%) vs. -66% (-86%, -30%), < 0.001], respectively). No significant differences were observed between the two groups in the other parameters (age, pathological type, distant metastasis, follow-up time, AJCC TNM stage, initial I treatment activity, and I treatment frequency) after PSM (all > 0.05).
[CONCLUSION] In patients with DTC and LNM, LNM uptake of Tc-pertechnetate is a rare phenomenon. Patients with Tc-pertechnetate-avid LNMs were more likely to benefit from I therapy, even after adjustment for age, I treatment frequency, and initial I activity.
같은 제1저자의 인용 많은 논문 (5)
- A graded approach in East Asian personalized lower blepharoplasty: A retrospective study spanning 12 years.
- Review of complications in double eyelid surgery.
- Spatial transcriptomics and single-cell analyses reveal the role of the cisplatin-resistant gene panel in NSCLC progression and the tumor microenvironment, identifying LOXL2 as a potential therapeutic target.
- Association between C-reactive protein-to-albumin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study.
- CX3CL1/CX3CR1 axis in liver disease: context-dependent roles and balance.